{"schema_version":"secwatch.filing_event.v1","accession":"0000927066-24-000089","form_type":"8-K","ticker":"DVA","cik":"0000927066","company_name":"DAVITA INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.525863+00:00","generated_at":"2026-06-03T01:41:01.721020+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DaVita Q1 2024 net income $240M, EPS $2.65; revenue $3.07B","bullets":["Revenue $3.071B; operating income $484M; adjusted operating income $463M.","Diluted EPS $2.65 (up from $1.25 in Q1 2023); adjusted diluted EPS $2.38 (vs $1.58).","Operating cash flow $(135)M; free cash flow $(327)M due to working capital timing.","Repurchased 2.1M shares at average price $112.76 per share.","CEO cites continued operational discipline and investment in clinical excellence."],"urls":{"canonical":"https://secwatch.observer/filing/0000927066-24-000089","json":"https://secwatch.observer/filing/0000927066-24-000089.json","markdown":"https://secwatch.observer/filing/0000927066-24-000089.md","text":"https://secwatch.observer/filing/0000927066-24-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/927066/000092706624000089/0000927066-24-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/927066/000092706624000089/dva-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:41:01.721020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"021634f87a5d7f83da1ed3299a9a35d469b8626f","claim":"DAVITA INC. reported for the quarter ended March 31, 2024 results: revenue $3.071 billion, net income $240, EPS $2.65.","evidence_excerpt":"deliver clinical excellence,” said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: • Consolidated revenues were $3.071 billion. • Operating income was $484 million and adjusted operating income was $463 million. • Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38. •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/927066/000092706624000089/0000927066-24-000089-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.071 billion"},{"label":"Net income","value":"$240"},{"label":"EPS","value":"$2.65"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}